Hertility Health raises £4.2m in seed funding led by LocalGlobe and Venrex to expand diagnostics
The seed round was led by LocalGlobe and Venrex to support product expansion and clinical trials.
Hertility Health provides comprehensive hormonal testing, fertility insights, and healthcare support for women. The company uses a science-driven platform to make reproductive healthcare more accessible, affordable, and personalised.
Hertility Health has secured £4.2m in seed funding to expand its diagnostic capabilities and clinical trials. The investment round was led by LocalGlobe and Venrex, alongside several strategic angels including Evelyn Bourke and Matt Robinson. The capital will support the company as it develops new testing products and works to cut diagnosis times for common reproductive conditions.
From the founder
"We live in a society that expects us to tolerate pain and mask our symptoms. Some women spend over ten years on their contraception, never fully knowing if there might be something wrong"
Helen O'Neill
CEO and Founder at Hertility Health
Investor perspective
"The world class team of experts, scientists and researchers at Hertility Health are what make it a real game-changer in the industry"
Julia Hawkins
General Partner, LocalGlobe
Use of funds
- 01Continue product development
- 02Fund research and development
Investors
Categories
About the company
Hertility Health
Hertility Health offers comprehensive hormonal testing, fertility insights, and reproductive healthcare support.